GALT - צמיחת מכירות משנה לשנה (TTM) galectintherapeutics.com

Investments in the development of galectin inhibitors create a foundation for bringing belapectin to the liver fibrosis therapy market. The year-over-year product sales dynamics for the TTM clearly demonstrate this progress, where the 0.00 metric determines this level. Stable demand for vital biologics makes Galectin Therapeutics (GALT) independent of economic cycles and global GDP fluctuations.
Galectin Therapeutics Inc. - פילוחים אנליטיים ומדדי מפתח (GALT)

For the biopharmaceutical company Galectin Therapeutics (GALT), which focuses on developing Belapectin to combat liver cirrhosis, operating revenue is often episodic in nature. By analyzing the 12-month year-over-year revenue growth rate on the GURU.Markets platform, an investor can view a daily comparison of rolling annual metrics, which filters out market noise and provides an objective assessment of the business's commercial development stage.